Can uniQure’s AMT-260 gene therapy become an alternative to epilepsy surgery?
Explore whether uniQure’s AMT-260 gene therapy can rival epilepsy surgery after early seizure reductions in a small first-in-human cohort.
Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy
Find out how uniQure’s AMT-260 early epilepsy data could shape the next test for brain-delivered gene therapy.